{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:58:47Z","timestamp":1789181927035,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672391"],"award-info":[{"award-number":["81672391"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972275"],"award-info":[{"award-number":["81972275"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81472269"],"award-info":[{"award-number":["81472269"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Major Innovation Project of Shandong Province","award":["2018CXGC1217"],"award-info":[{"award-number":["2018CXGC1217"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00109-019-01868-9","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T20:02:21Z","timestamp":1577131341000},"page":"221-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma"],"prefix":"10.1007","volume":"98","author":[{"given":"Xiaomin","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueke","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1030-2232","authenticated-orcid":false,"given":"Lihui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"1868_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/liv.13031","volume":"36","author":"C Margini","year":"2016","unstructured":"Margini C, Dufour JF (2016) The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver international : official journal of the International Association for the Study of the Liver 36:317\u2013324","journal-title":"Liver international : official journal of the International Association for the Study of the Liver"},{"key":"1868_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jjco\/hyx180","volume":"48","author":"M Ikeda","year":"2018","unstructured":"Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J (2018) Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol 48:103\u2013114","journal-title":"Jpn J Clin Oncol"},{"key":"1868_CR3","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.immuni.2014.12.010","volume":"41","author":"R Caruso","year":"2014","unstructured":"Caruso R, Warner N, Inohara N, Nunez G (2014) NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity 41:898\u2013908","journal-title":"Immunity"},{"key":"1868_CR4","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.it.2017.07.004","volume":"38","author":"AM Keestra-Gounder","year":"2017","unstructured":"Keestra-Gounder AM, Tsolis RM (2017) NOD1 and NOD2: beyond peptidoglycan sensing. Trends Immunol 38:758\u2013767","journal-title":"Trends Immunol"},{"issue":"2","key":"1868_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/ijms18020404","volume":"18","author":"Kai Li","year":"2017","unstructured":"Li K, Qu S, Chen X, Wu Q, Shi M (2017) Promising targets for Cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways. International journal of molecular sciences 18. DOI https:\/\/doi.org\/10.3390\/ijms18020404","journal-title":"International Journal of Molecular Sciences"},{"key":"1868_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2326-6066.CIR-16-0269","volume":"5","author":"R Karki","year":"2017","unstructured":"Karki R, Man SM, Kanneganti TD (2017) Inflammasomes and Cancer. Cancer immunology research 5:94\u201399","journal-title":"Cancer immunology research"},{"key":"1868_CR7","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1111\/jcmm.13842","volume":"22","author":"D Chai","year":"2018","unstructured":"Chai D, Liu N, Li H, Wang G, Song J, Fang L, Lu Z, Yao H, Zheng J (2018) H1\/pAIM2 nanoparticles exert anti-tumour effects that is associated with the inflammasome activation in renal carcinoma. J Cell Mol Med 22:5670\u20135681","journal-title":"J Cell Mol Med"},{"key":"1868_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.humimm.2011.06.003","volume":"72","author":"AG Kutikhin","year":"2011","unstructured":"Kutikhin AG (2011) Role of NOD1\/CARD4 and NOD2\/CARD15 gene polymorphisms in cancer etiology. Hum Immunol 72:955\u2013968","journal-title":"Hum Immunol"},{"key":"1868_CR9","doi-asserted-by":"crossref","first-page":"36185","DOI":"10.18632\/oncotarget.9154","volume":"7","author":"X Ma","year":"2016","unstructured":"Ma X, Guo P, Qiu Y, Mu K, Zhu L, Zhao W, Li T, Han L (2016) Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway. Oncotarget 7:36185\u201336197","journal-title":"Oncotarget"},{"key":"1868_CR10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/labinvest.2015.63","volume":"95","author":"Q Wei","year":"2015","unstructured":"Wei Q, Guo P, Mu K, Zhang Y, Zhao W, Huai W, Qiu Y, Li T, Ma X, Liu Y et al (2015) Estrogen suppresses hepatocellular carcinoma cells through ERbeta-mediated upregulation of the NLRP3 inflammasome. Laboratory investigation; a journal of technical methods and pathology 95:804\u2013816","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"key":"1868_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/onc.2017.349","volume":"37","author":"P Guo","year":"2018","unstructured":"Guo P, Ma X, Zhao W, Huai W, Li T, Qiu Y, Zhang Y, Han L (2018) TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex. Oncogene 37:478\u2013488","journal-title":"Oncogene"},{"key":"1868_CR12","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","volume":"140","author":"S Lim","year":"2013","unstructured":"Lim S, Kaldis P (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140:3079\u20133093","journal-title":"Development"},{"key":"1868_CR13","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/febs.12669","volume":"281","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Iino M (2014) Knockdown of Sec8 promotes cell-cycle arrest at G1\/S phase by inducing p21 via control of FOXO proteins. FEBS J 281:1068\u20131084","journal-title":"FEBS J"},{"key":"1868_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbrc.2014.02.105","volume":"446","author":"H Xu","year":"2014","unstructured":"Xu H, Wang Z, Jin S, Hao H, Zheng L, Zhou B, Zhang W, Lv H, Yuan Y (2014) Dux4 induces cell cycle arrest at G1 phase through upregulation of p21 expression. Biochem Biophys Res Commun 446:235\u2013240","journal-title":"Biochem Biophys Res Commun"},{"key":"1868_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","volume":"94","author":"R Roskoski Jr","year":"2015","unstructured":"Roskoski R Jr (2015) Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res 94:9\u201325","journal-title":"Pharmacol Res"},{"key":"1868_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007091","volume":"13","author":"P Houtz","year":"2017","unstructured":"Houtz P, Bonfini A, Liu X, Revah J, Guillou A, Poidevin M, Hens K, Huang HY, Deplancke B, Tsai YC, Buchon N (2017) Hippo, TGF-beta, and Src-MAPK pathways regulate transcription of the upd3 cytokine in Drosophila enterocytes upon bacterial infection. PLoS Genet 13:e1007091. https:\/\/doi.org\/10.1371\/journal.pgen.1007091","journal-title":"PLoS Genet"},{"key":"1868_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/CBM-160102","volume":"18","author":"K Huang","year":"2017","unstructured":"Huang K, Chen J, Yang MS, Tang YJ, Pan F (2017) Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells. Cancer biomarkers : section A of Disease markers 18:231\u2013239","journal-title":"Cancer biomarkers : section A of Disease markers"},{"key":"1868_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1124\/jpet.117.240507","volume":"363","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Guo X, Choksi R (2017) Activation of focal adhesion kinase and Src mediates acquired Sorafenib resistance in A549 human lung adenocarcinoma Xenografts. J Pharmacol Exp Ther 363:428\u2013443","journal-title":"J Pharmacol Exp Ther"},{"key":"1868_CR19","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1159\/000489153","volume":"46","author":"T Liu","year":"2018","unstructured":"Liu T, Wu X, Li Y, Lu W, Zheng F, Zhang C, Long Q, Qiu H, Li Y, Ge Q et al (2018) RBFOX3 regulates the Chemosensitivity of Cancer cells to 5-fluorouracil via the PI3K\/AKT, EMT and cytochrome-C\/Caspase pathways. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 46:1365\u20131380","journal-title":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology"},{"key":"1868_CR20","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","volume":"20","author":"JM Llovet","year":"2014","unstructured":"Llovet JM, Hernandez-Gea V (2014) Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clinical cancer research : an official journal of the American Association for Cancer Research 20:2072\u20132079","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"1868_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1517\/14656566.2011.546346","volume":"12","author":"YS Guan","year":"2011","unstructured":"Guan YS, He Q (2011) Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Expert Opin Pharmacother 12:303\u2013313","journal-title":"Expert Opin Pharmacother"},{"key":"1868_CR22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.4254\/wjh.v7.i8.1041","volume":"7","author":"S Colagrande","year":"2015","unstructured":"Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL (2015) Advanced hepatocellular carcinoma and sorafenib: diagnosis, indications, clinical and radiological follow-up. World J Hepatol 7:1041\u20131053","journal-title":"World J Hepatol"},{"key":"1868_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.micinf.2016.03.014","volume":"18","author":"SJ Robertson","year":"2016","unstructured":"Robertson SJ, Geddes K, Maisonneuve C, Streutker CJ, Philpott DJ (2016) Resilience of the intestinal microbiota following pathogenic bacterial infection is independent of innate immunity mediated by NOD1 or NOD2. Microbes Infect 18:460\u2013471","journal-title":"Microbes Infect"},{"key":"1868_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1099\/jgv.0.000401","volume":"97","author":"S Coutermarsh-Ott","year":"2016","unstructured":"Coutermarsh-Ott S, Eden K, Allen IC (2016) Beyond the inflammasome: regulatory NOD-like receptor modulation of the host immune response following virus exposure. The Journal of general virology 97:825\u2013838","journal-title":"The Journal of general virology"},{"key":"1868_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3904\/kjim.2015.409","volume":"33","author":"WG Shin","year":"2018","unstructured":"Shin WG, Park BJ, Lee SJ, Kim JG (2018) Infection of human intestinal epithelial cells by invasive bacteria activates NF-kappaB and increases ICAM-1 expression through NOD1. The Korean journal of internal medicine 33:81\u201390","journal-title":"The Korean journal of internal medicine"},{"key":"1868_CR26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.4161\/cc.25099","volume":"12","author":"C Wang","year":"2013","unstructured":"Wang C, Cigliano A, Delogu S, Armbruster J, Dombrowski F, Evert M, Chen X, Calvisi DF (2013) Functional crosstalk between AKT\/mTOR and Ras\/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle 12:1999\u20132010","journal-title":"Cell Cycle"},{"key":"1868_CR27","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/hep.23836","volume":"52","author":"H Hikita","year":"2010","unstructured":"Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N (2010) The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 52:1310\u20131321","journal-title":"Hepatology"},{"key":"1868_CR28","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","volume":"324","author":"R Roskoski Jr","year":"2004","unstructured":"Roskoski R Jr (2004) Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 324:1155\u20131164","journal-title":"Biochem Biophys Res Commun"},{"key":"1868_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bbrc.2018.05.137","volume":"502","author":"HY Min","year":"2018","unstructured":"Min HY, Jung Y, Park KH, Oh WK, Lee HY (2018) Erybraedin A is a potential Src inhibitor that blocks the adhesion and viability of non-small-cell lung cancer cells. Biochem Biophys Res Commun 502:145\u2013151","journal-title":"Biochem Biophys Res Commun"},{"key":"1868_CR30","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1038\/s41598-017-04301-8","volume":"7","author":"A Stanley","year":"2017","unstructured":"Stanley A, Ashrafi GH, Seddon AM, Modjtahedi H (2017) Synergistic effects of various her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Sci Rep 7:3964","journal-title":"Sci Rep"},{"key":"1868_CR31","doi-asserted-by":"publisher","first-page":"10194","DOI":"10.1038\/srep10194","volume":"5","author":"R Thakur","year":"2015","unstructured":"Thakur R, Trivedi R, Rastogi N, Singh M, Mishra DP (2015) Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep 5:10194","journal-title":"Sci Rep"},{"key":"1868_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1634\/theoncologist.2010-0408","volume":"16","author":"LN Puls","year":"2011","unstructured":"Puls LN, Eadens M, Messersmith W (2011) Current status of SRC inhibitors in solid tumor malignancies. Oncologist 16:566\u2013578","journal-title":"Oncologist"},{"key":"1868_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1139\/bcb-2013-0106","volume":"92","author":"N Calvo","year":"2014","unstructured":"Calvo N, Martin MJ, de Boland AR, Gentili C (2014) Involvement of ERK1\/2, p38 MAPK, and PI3K\/Akt signaling pathways in the regulation of cell cycle progression by PTHrP in colon adenocarcinoma cells. Biochemistry and cell biology = Biochimie et biologie cellulaire 92:305\u2013315","journal-title":"Biochemistry and cell biology = Biochimie et biologie cellulaire"},{"key":"1868_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3109\/10799893.2015.1030412","volume":"35","author":"Y Sun","year":"2015","unstructured":"Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF (2015) Signaling pathway of MAPK\/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res 35:600\u2013604","journal-title":"J Recept Signal Transduct Res"},{"key":"1868_CR35","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/bjc.2014.327","volume":"111","author":"G Peiro","year":"2014","unstructured":"Peiro G, Ortiz-Martinez F, Gallardo A, Perez-Balaguer A, Sanchez-Paya J, Ponce JJ, Tibau A, Lopez-Vilaro L, Escuin D, Adrover E et al (2014) Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. Br J Cancer 111:689\u2013695","journal-title":"Br J Cancer"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-019-01868-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-019-01868-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-019-01868-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:05:11Z","timestamp":1608595511000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-019-01868-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1007\/s00109-019-01868-9","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]},"assertion":[{"value":"12 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}